new version V2017

Dabigatran antithrombotics

Pradax - Pradaxa      

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

acute coronary syndrome

REDEEM, 2009dabigatranplaceboNegativeNCT00621855

atrial fibrillation

RE-LY 150mg (2nd prevention subgroup) dabigatran 150mgwarfarin Exploratory Suggesting
phase 2 dabigatrandabigatranwarfarin standard dose Exploratory - NCT01136408
PETRO (150mg), 2007dabigatran 150mgwarfarin standard dose Exploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard dose Risk of bias Suggesting NCT00262600
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard dose Risk of bias SuggestingNCT00262600
RE-LY 110mg (2nd prevention subgroup) , 2010dabigatran 100mgwarfarin Exploratory Suggesting

post acute coronary syndromes

REDEEM, 2009dabigatranplaceboNegativeNCT00621855

post myocardial infarction

REDEEM, 2009dabigatranplaceboNegativeNCT00621855

thrombosis prevention

RE-NOVATE 2dabigatran 220mgenoxaparinhip surgery Low risk of bias NegativeNCT00657150
RE-NOVATE (220mg), 2007dabigatran 220mgenoxaparinhip surgery Low risk of bias NegativeNCT00168818
RE-NOVATE (150mg), 2007dabigatran 150mgenoxaparinhip surgery Low risk of bias Negative NCT00168818
RE-MODEL (220mg), 2007dabigatran 220mgenoxaparin (europe regimen)knee surgery Low risk of bias Negative
RE-MODEL (150mg), 2007dabigatran 150mgenoxaparin (europe regimen)knee surgery Low risk of bias Negative
RE-MOBILIZE (220mg), 2008dabigatran 220mgenoxaparin (US regimen)knee surgery Low risk of bias Negative
RE-MOBILIZE (150mg), 2008dabigatran 150mgenoxaparin (US regimen)knee surgery Low risk of bias Negative

venous thrombosis

RE-COVER, 2009heparin/dabigatranheparin/VKA Low risk of bias SuggestingNCT00291330
RE-SONATE, 2011dabigatrandiscontinuationSuggestingNCT00558259
RE-COVER II, 2011heparin/dabigatranheparin/VKASuggestingNCT00680186
RE-MEDY, 2011dabigatranwarfarin Low risk of bias SuggestingNCT00329238